联合王国国民保健制度批准林扎戈利克斯避孕药用于内分泌硬化,每年帮助多达1 000名妇女。 The UK NHS approves Linzagolix pill for endometriosis, aiding up to 1,000 women yearly.

联合王国国家保健服务局批准了一种名为Linzagolix(或Yselty)的新的每日避孕药,用于治疗子宫内硬化症,这一疾病影响到联合王国大约150万妇女。 The UK's National Health Service has approved a new daily pill called Linzagolix, or Yselty, to treat endometriosis, a condition affecting around 1.5 million women in the UK. 每天服用一次的避孕药每年可惠及多达1 000名妇女,阻塞导致严重疼痛和重时段等症状的荷尔蒙。 The pill, taken once daily, could benefit up to 1,000 women annually by blocking hormones that contribute to symptoms such as severe pain and heavy periods. 这是在3月批准Relugolix综合疗法后,批准用于内分泌硬化的第二个每日避孕药。 This is the second daily pill approved for endometriosis, following the March approval of relugolix combination therapy. Linzagolix需要额外的荷尔蒙疗法,以防止更年期症状和骨折。 Linzagolix requires additional hormonal therapy to prevent menopause-like symptoms and bone loss.